Almirall S.A. Aktie
8,89 €
Deine Einschätzung
Almirall S.A. Aktie
Was spricht für und gegen Almirall S.A. in den nächsten Jahren?
Pro
Kontra
Rendite von Almirall S.A. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Almirall S.A. | 0,28 % | 0,62 % | -6,62 % | -6,82 % | 4,90 % | -39,27 % | - |
Sihuan Pharmaceutical Holdings Group Ltd. | - | -3,45 % | -5,88 % | -22,76 % | -18,25 % | -76,47 % | -62,34 % |
Orion Corp. B | -0,02 % | -0,45 % | 16,91 % | 32,30 % | 18,66 % | 33,89 % | 41,42 % |
Recordati SpA | 0,68 % | 1,78 % | 0,59 % | 12,51 % | 5,33 % | -9,50 % | 30,14 % |
Kommentare
News
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in
NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
Almirall S.A. (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming